RBC Capital Maintains Outperform on Globus Medical, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has maintained an 'Outperform' rating on Globus Medical and raised its price target from $78 to $80, indicating confidence in the company's future performance.
October 08, 2024 | 6:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its 'Outperform' rating for Globus Medical and increased the price target from $78 to $80, suggesting a positive outlook for the company's stock.
The 'Outperform' rating and increased price target from a reputable analyst firm like RBC Capital suggest a positive sentiment towards Globus Medical's stock. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100